PNT · Point Biopharma Global Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue | $0 | - | - |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| R&D | $82.05M | $9.14M | - |
| SG&A | $19.01M | $3.97M | - |
| Total Operating Expenses | $101.06M | $13.11M | - |
| D&A | $0 | - | - |
| Operating Income | $125.52M | ($13.11M) | - |
| Interest Expense | - | - | - |
| Income Tax | $31.29M | $87.9K | - |
| Net Income | $98.29M | ($13.37M) | - |
| EPS - Basic | $1.04 | ($0.34) | - |
| EPS - Diluted | $1.02 | ($0.34) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash & Equivalents | $286.43M | $238.82M | $0 |
| Accounts Receivable | - | - | - |
| Inventory | - | - | - |
| Accounts Payable | $7.70M | $1.74M | $5.1K |
| Current Assets | $530.82M | $243.85M | $1.20M |
| Total Assets | $578.32M | $263.26M | $136.91M |
| Current Liabilities | $79.74M | $7.98M | $117.7K |
| Long-term Debt | - | - | - |
| Total Liabilities | $91.37M | $8.05M | $4.87M |
| Stockholders' Equity | $486.95M | $255.21M | $5.00M |
| Retained Earnings | $39.01M | ($59.28M) | ($311.5K) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Operating Cash Flow | $183.52M | ($8.30M) | - |
| Investing Cash Flow | ($266.26M) | ($9.80M) | - |
| Financing Cash Flow | $130.36M | $28.65M | - |
| CapEx | $12.77M | $9.80M | - |
| Free Cash Flow | $170.75M | ($18.10M) | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Profitability | |||
| Gross margin | - | - | - |
| Operating margin | - | - | - |
| EBITDA margin | - | - | - |
| Net margin | - | - | - |
| Free cash flow margin | - | - | - |
| FCF / Net income | 1.74 | 1.35 | - |
| R&D / Revenue | - | - | - |
| SG&A / Revenue | - | - | - |
| Effective tax rate | 24.1% | - | - |
| Return on assets | 17.0% | -5.1% | - |
| Return on equity | 20.2% | -5.2% | - |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 6.66 | 30.56 | 10.20 |
| Quick ratio | 6.66 | 30.56 | 10.20 |
| Cash ratio | 3.59 | 29.93 | 0.00 |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | - | - | - |
| Equity multiplier | 1.19 | 1.03 | 27.38 |
| Liabilities / Assets | 0.16 | 0.03 | 0.04 |
| Efficiency | |||
| Asset turnover | 0.00 | - | - |
| Inventory turnover | - | - | - |
| Days sales outstanding | - | - | - |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | - | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | - | - | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | - | - | - |
| Net income growth (YoY) | - | - | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | - | - | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | 90.8% | 5004.3% | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
3.53
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing POINT Biopharma Global Inc. against the 5 most active filers in the same SIC group.